article · Journal of Clinical Pharmacy and Therapeutics
Venlafaxine is a standard antidepressant that is broken down in the body primarily by the enzyme CYP2D6 into an active compound called O-desmethylvenlafaxine. In a study of one hundred patients, measuring the ratio of this active compound to the original drug revealed substantial variation in how people process the medication. Genetic testing confirmed that individuals with very low conversion ratios were poor metabolisers carrying specific genetic variants, while those with very high ratios were ultra rapid metabolisers. Patients classified as poor metabolisers experienced significantly more adverse effects, most notably gastrointestinal issues such as nausea, vomiting, and diarrhoea, alongside reduced blood sodium levels. While genetic differences strongly influenced drug metabolism and side effect vulnerability, overall treatment efficacy did not differ significantly between patient groups.
Understanding how individual genetics alter medication processing helps explain why certain patients suffer severe adverse reactions to standard treatments. By demonstrating that poor CYP2D6 metabolisers face a greater burden of side effects without a difference in therapeutic efficacy, these findings highlight the clinical value of tailoring antidepressant treatment to minimise unnecessary patient distress and adverse complications.
This clinical study provides evidence that CYP2D6 genotyping or metabolic ratio profiling could assist clinicians and diagnostic laboratories in identifying depression patients at high risk of adverse reactions to venlafaxine. While the study demonstrates applied clinical testing in a cohort of one hundred patients, routine adoption into clinical decision-making or dedicated companion diagnostic kits would require validated diagnostic workflows and formal clinical implementation guidelines.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND: Venlafaxine (V) is a mixed serotonin and noradrenaline reuptake inhibitor used as a first-line treatment of depressive disorders. It is metabolized primarily by the highly polymorphic cytochrome P450 (CYP) enzyme CYP2D6 to yield a pharmacologically active metabolite, O-desmethylvenlafaxine (ODV), and to a lesser extent by CYP3A4, to yield N-desmethylvenlafaxine (NDV). OBJECTIVES: The aim of this study was to assess whether the O-demethylation phenotype of V has an impact on the pharmacokinetics and clinical outcome. METHOD: In 100 patients treated with V, serum concentrations of V, ODV and NDV and the ratios of concentrations ODV/V as a measure of O-demethylation were determined. Individuals exhibiting abnormally high or low metabolic ratios of ODV/V were selected for genotyping. Clinical effects were monitored by the Clinical Global Impressions Scale and side effects by the UKU (Udvalg for Kliniske Undersogelser Side Effect Rating Scale) rating scale. RESULTS: There was wide inter-individual variability in ODV/V ratios. The median ratio ODV/V was 1.8 and the 10th and 90th percentiles 0.3 and 5.2, respectively. Individuals with ODV/V ratios below 0.3 were all identified as poor metabolizers (PM), with the genotypes *6/*4 (n = 1), *5/*4 (n = 2) or *6/*6 (n = 1). Individuals with ratios above 5.2 were all ultra rapid metabolizers (UM, n = 6) due to gene duplications. Five individuals with intermediate metabolic activity (ODV/V, 1.1 +/- 0.8) were heterozygotes with the CYP2D6*4 genotype, and one patient with an intermediate metabolic ratio of 4.8 had the genotype *4/2x*1. Clinical outcome measurements revealed that patients with ODV/V ratios below 0.3 had more side effects (P < 0.005) and reduced serum concentrations of sodium (P < 0.05) in comparison with other patients. Gastrointestinal side effects, notably nausea, vomiting and diarrhoea were the most common. Differences in therapeutic efficacy were not significant between the different phenotypes. CONCLUSION: The O-demethylation phenotype of V depends strongly on the CYP2D6 genotype. A PM phenotype of CYP2D6 increases the risk of side effects.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1111/j.1365-2710.2006.00763.x
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
